Endocrine Abstracts

Background: Capecitabine-Temozolomide (CapTem) is an effective oral chemotherapy regimen for NETs. Both drugs are radiosensitizers. A feasibility study of integrated CapTem and Y90 transarterial radioembolization (TARE) in patients with grade 2 neuroendocrine tumor (NET) liver metastases reported encouraging objective response rate (ORR) and progression-free survival (PFS). This study expands that report to a larger cohort with long-term oncologic follow-up.<p class="abste...

Background: Capecitabine and temozolomide (CapTem) are classic radiosensitizers used in combination with radiation therapy for many cancers. A feasibility study of integrated CapTem and Y90 transarterial radioembolization (TARE) for neuroendocrine tumors (NETs) suggests synergy with PFS of 31 months exceeding historical controls. The impact of duration of chemotherapy after TARE on PFS is not known.Methods: 36 subjects with liver-domianant grade 2 metast...

Background: Telotristat etiprate (TE), an oral tryptophan hydroxylase inhibitor, is intended to treat carcinoid syndrome (CS) by reducing serotonin production. TE was evaluated in TELESTAR, a phase 3 study; the primary endpoint showed significant reductions in bowel movement (BM) frequency for 2 TE dosages + standard of care (SOC) vs. SOC. TELESTAR patients had CS inadequately controlled on somatostatin analog therapy with ≥4 BMs per day. They were interviewed about base...